PR-Section 8 and 9

PTO- 1963

Approved for use through 10/31/2021. OMB 0651-0055

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

---

PTO- 1963

Approved for use through 10/31/2021. OMB 0651-0055

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Combined Declaration of Use and/or Excusable Nonuse/Application for Renewal of Registration of a Mark under Sections 8 & 9

To the Commissioner for Trademarks:

REGISTRATION NUMBER: 2451009
REGISTRATION DATE: 05/15/2001

MARK: (Stylized and/or with Design, ENGERIX-B (see, mark))

Current: The owner, GLAXOSMITHKLINE BIOLOGICALS S.A., a corporation of BELGIUM (BEX), having an address of
      Rue de l'Institut 89
      B-1330 Rixensart,
      Belgium
      XXXX
      919-483-1803
      704-625-9190

Proposed: The owner, GLAXOSMITHKLINE BIOLOGICALS S.A., a corporation of Belgium, having an address of
      Rue de l'Institut 89
      Rixensart, B-1330
      Belgium
      XXXX
is filing a Combined Declaration of Use and/or Excusable Nonuse/Application for Renewal of Registration of a Mark under Sections 8 & 9.

For International Class 016, the mark is in use in commerce on or in connection with all goods/services, or to indicate membership in the collective membership organization, listed in the existing registration for this specific class: printed materials, namely, pamphlets relating to Hepatitis B and vaccines to prevent Hepatitis B ; or, the owner is making the listed excusable nonuse claim.

The owner is submitting one(or more) specimen(s) showing the mark as used in commerce on or in connection with any item in this class, consisting of a(n) resource used for Energix-B vaccine.

Original PDF file:
SPN0-15251561-20210412151 434710607_._VPH_Dosing_Le ave_Behind_2019.pdf
Converted PDF file(s) (2 pages)
Specimen File1
Specimen File2

Webpage URL: None Provided
Webpage Date of Access: None Provided
The owner's/holder's current attorney information: Angela L. Wilson. Angela L. Wilson of GlaxoSmithKline, is located at

      Legal Global Trademarks, Mailstop: 5.5A
      Five Moore Drive
      Research Triangle Park, North Carolina 27709-0183
      United States
The docket/reference number is PRJ/7057245/.

The phone number is 919 483-0008.

The fax number is 919 483-7988.

The email address is trademarks@gsk.com

The owner's/holder's proposed attorney information: Merilee J. Arevalo. Other appointed attorneys are Christopher M. Hanes, Arrielle Millstein. Merilee J. Arevalo of GlaxoSmithKline, is a member of the XX bar, admitted to the bar in XXXX, bar membership no. XXX, and the attorney(s) is located at

      LBP, Mailstop: 5.5A
      Five Moore Drive
      Research Triangle Park, North Carolina 27709-0183
      United States
The docket/reference number is 81238938.

The phone number is 919-323-6951.

The email address is trademarks@gsk.com

Merilee J. Arevalo submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court of a U.S. state, the District of Columbia, or any U.S. Commonwealth or territory.
The current domestic representative's information: Angela L. Wilson. 

The phone number is 919 483-0008.

The fax number is 919 483-7988.

The email address is trademarks@gsk.com

The proposed domestic representative's information: Merilee J. Arevalo. Merilee J. Arevalo of GlaxoSmithKline, is appointed as owner's/holder's representative upon whom notice or process in the proceedings affecting the mark may be served. Merilee J. Arevalo is located at

      LBP, Mailstop: 5.5A
      Five Moore Drive
      Research Triangle Park, North Carolina 27709-0183
      United States

The phone number is 919-323-6951.

The email address is trademarks@gsk.com
Correspondence Information (current):
      Angela L. Wilson
      PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@gsk.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED

The docket/reference number is PRJ/7057245/.
Correspondence Information (proposed):
      Merilee J. Arevalo
      PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@gsk.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED

The docket/reference number is 81238938.

Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).

A fee payment in the amount of $525 will be submitted with the form, representing payment for 1 class(es), plus any additional grace period fee, if necessary.


Declaration

	Unless the owner has specifically claimed excusable nonuse, the mark is in use in commerce on or in connection with the goods/services or to indicate membership in the collective membership organization identified above, as evidenced by the attached specimen(s).
	Unless the owner has specifically claimed excusable nonuse, the specimen(s) shows the mark as currently used in commerce on or in connection with the goods/services/collective membership organization.
	The registrant requests that the registration be renewed for the goods/services/collective organization identified above.
	To the best of the signatory's knowledge, information, and belief, formed after an inquiry reasonable under the circumstances, the allegations and other factual contentions made above have evidentiary support.
	The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements and the like may jeopardize the validity of this submission and the registration, declares that all statements made of his/her own knowledge are true and all statements made on information and belief are believed to be true.

Signature: /Merilee J. Arevalo/    Date: 04/12/2021
Signatory's Name: Merilee J. Arevalo
Signatory's Position: Attorney of Record, New Jersey Bar member
Signatory's Phone: 919-323-6951
Signature method: Sent to third party for signature


Mailing Address (current):
   GlaxoSmithKline
   Five Moore Drive
   Research Triangle Park, North Carolina 27709-0183

Mailing Address (proposed):
   GlaxoSmithKline
   Five Moore Drive
   Research Triangle Park, North Carolina 27709-0183

Serial Number: 76050489
Internet Transmission Date: Tue Apr 13 08:22:04 ET 2021
TEAS Stamp: USPTO/S08N09-XXX.XX.XX.X-202104130822047
61548-2451009-7706e72105376fd238f827a20e
2e06714935ae6717619c1be106dd12266b82c34f
8-DA-22024990-20210412151434710607